# cAMP/PKA signaling in endocrine hypertension: genetic mechanisms and pathophysiological insights

## TL;DR

This paper explores how genetic changes in the cAMP/PKA signaling pathway contribute to various types of high blood pressure, highlighting new insights into their causes and treatment possibilities.

## Contribution

The paper provides new insights into the genetic mechanisms of endocrine hypertension through the cAMP/PKA signaling pathway.

## Key findings

- Germline and somatic variants in GNAS and PRKAR1A are linked to cortisol excess and adrenal disorders.
- Phosphodiesterase gene variants like PDE11A and PDE8B are associated with Cushing syndrome and adrenal hyperplasia.
- PDE3A gain-of-function variants are connected to a familial form of salt-independent hypertension.

## Abstract

The cyclic adenosine monophosphate (cAMP)–protein kinase A (PKA) signaling pathway plays a central role in adrenal function, steroidogenesis, and blood pressure regulation. Increasing evidence suggests that dysregulation of this pathway contributes to several forms of hypertension, both endocrine and non-endocrine. A growing number of germline and somatic alterations affecting components of the cAMP/PKA axis have been implicated as key drivers of hypertensive disorders. Among these, activating pathogenic variants (PV) in GNAS, which encodes the stimulatory G protein α-subunit (Gsα) responsible for cAMP production, have been linked to cortisol excess. Mosaic GNAS PV cause McCune-Albright syndrome, which may present with ACTH-independent Cushing syndrome, while somatic GNAS PV have been identified in cortisol-producing adrenal adenomas. Germline inactivating variants in PRKAR1A are associated with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD). Furthermore, germline alterations in phosphodiesterases such as PDE11A and PDE8B, which impair cAMP degradation, have been associated with Cushing syndrome and micronodular adrenal hyperplasia. Somatic activating PV in PRKACA, the gene encoding the catalytic subunit of PKA, have also been described in cortisol-producing adenomas. In primary aldosteronism, recent studies—including data from our group—suggest that germline variants in PDE2A and PDE3B may contribute to bilateral adrenal hyperplasia and autonomous aldosterone production by modulating intracellular cAMP levels. Additionally, gain-of-function PV in PDE3A have been associated with a familial form of salt-independent hypertension characterized by enhanced PKA signaling and vascular remodeling. This expanding body of evidence underscores the critical role of the cAMP/PKA pathway in the pathophysiology of distinct hypertensive phenotypes and highlights novel molecular mechanisms and potential therapeutic targets that merit further investigation.